Morgan Stanley resumed coverage of Royalty Pharma (RPRX) with an Overweight rating and $51 price target The firm cites se the company’s diversified portfolio and insulation from potential tariffs, coupled with a growth profile above the peer average, as positives.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX: